Patient Support Services Contact Us
Image: Coherus Investors

Overview

Investors

A fully integrated biopharmaceutical company with a robust pipeline across multiple therapeutic areas.

Coherus is a commercial stage biopharmaceutical company with the mission to increase patient access to cost-effective medicines that can have a major impact on their lives and to deliver significant savings to the health care system.

In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

News
09/16/21
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – - Coherus and Junshi Biosciences plan to submit a BLA supplement for 1L ESCC in
09/15/21
- Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma - REDWOOD CITY, Calif. , and SHANGHAI, China , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd
09/13/21
REDWOOD CITY, Calif. and SHANGHAI, China , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study
09/10/21
REDWOOD CITY, Calif. , Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23 rd Annual H.C. Wainwright Global Investment Conference . The presentation will be made available at 7 a.m.
Events & Presentations